Accepted for Publication: May 18, 2011.
Author Contributions: The corresponding author takes full responsibility for the data, the analyses and interpretation, and the conduct of the research. All coauthors reviewed the manuscript. Acquisition of data: Qian, Cross, and Naismith. Analysis and interpretation of data: Qian, Cross, and Naismith. Critical revision of the manuscript for important intellectual content: Qian, Cross, and Naismith. Administrative, technical, and material support: Qian, Cross, and Naismith.
Financial Disclosure: Dr Qian has received speaking honoraria from Teva Neurosciences. Dr Cross has received research funding, clinical trial funding, honoraria, or consulting fees from the National Institutes of Health (NIH), National Multiple Sclerosis Society USA, Consortium of Multiple Sclerosis Centers, Genentech Inc, Bayer Healthcare, Biogen-Idec, Hoffmann-La Roche Inc, Teva Neuroscience, Acorda Therapeutics, Serono, Pfizer, and BioMS. Dr Naismith has received consulting fees and speaking honoraria from Acorda Therapeutics, Bayer Healthcare, Biogen Idec, EMD Serono, Genzyme Corporation, and Teva Neurosciences.
Funding/Support: This study was supported by the NIH (grants T32NS007205 to PQ, K23NS052430-01A1 to Dr Naismith and K24 RR017100 to Dr Cross); Manny and Rosalyn Rosenthal–Dr John L. Trotter Chair in Neuroimmunology (Dr Cross). This publication was made possible by Grant No. UL1 RR024992 from the National Center for Research Resources, a component of the NIH and NIH Roadmap for Medical Research.
Disclaimer: The contents of the study are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or NIH.
Additional Information: The corresponding author has full access to all the data and has the right to publish any and all data, separate and apart from the attitudes of the sponsor.